Drug Trial Radar · NCT02932306
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
820
Actual
Start
Nov 3, 2015
Primary completion
Feb 22, 2017
Study completion Feb 22, 2017
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \[EGSS\] of 3 \[moderate\] or 4 \[severe\]).
Conditions
- Acne
Interventions
IDP-121 LotionDrug
IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
IDP-121 Vehicle LotionDrug
IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12Time frame: Baseline (Day 0), Week 12
- Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12Time frame: Baseline, Week 12
- Percentage of Participants With Treatment Success at Week 12Time frame: Baseline, Week 12
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 36
Guntersville, Alabama
Valeant Site 14
Phoenix, Arizona
Valeant Site 28
Hot Springs, Arkansas
Valeant Site 38
Fountain Valley, California
Valeant Site 34
Manhattan Beach, California
Valeant Site 23
Oceanside, California
Valeant Site 35
Ranch Cucamonga, California
Valeant Site 20
San Diego, California
Valeant Site 32
Denver, Colorado
Valeant Site 10
Shelton, Connecticut
Valeant Site 02
Boynton Beach, Florida
Valeant Site 15
Coral Gables, Florida
Valeant Site 37
Miami, Florida
Valeant Site 39
Pembroke Pines, Florida
Valeant Site 01
West Palm Beach, Florida
Valeant Site 19
Boise, Idaho
Valeant Site 04
Arlington Heights, Illinois
Valeant Site 27
Carmel, Indiana
Valeant 12
Plainfield, Indiana
Valeant Site 09
Louisville, Kentucky
Valeant Site 16
Louisville, Kentucky
Valeant Site 33
Needham, Massachusetts
Valeant Site 11
Warren, Michigan
Valeant Site 08
Omaha, Nebraska
Valeant Site 25
Omaha, Nebraska
Valeant Site 13
Berlin, New Jersey
Valeant Site 03
Albuquerque, New Mexico
Valeant Site 26
New York, New York
Valeant Site 31
Stony Brook, New York
Valeant 05
Gresham, Oregon
Valeant Site 22
Fort Washington, Pennsylvania
Valeant Site 24
Charleston, South Carolina
Valeant Site 06
Dallas, Texas
Valeant Site 30
Houston, Texas
Valeant Site 17
Pflugerville, Texas
Valeant Site 07
San Antonio, Texas
Valeant 18
Webster, Texas
Valeant Site 29
Salt Lake City, Utah
Valeant Site 21
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.